This report talks about the overview of the CRO market in Japan. By reading this report, readers will understand the overall picture of the Japanese CRO market, including the market size trends, major CRO players, in addition to the competitive differences between local and global CROs.
The number of clinical trials in Japan has been recovering in recent years. The pharma inudstry has been conducting both global and regional studies. Also, pharma have outsourced clinical related works to CROs more and more. As a result, the Japanese CRO market has been expanding for the past over 10 years, and reached ¥172 billion in 2016.
The market has been largely occupied by Tier 1 CROs; EPS, CMIC, Quintiles and Parexel. Recently, Tier 2 companies; A2 and M3, have been emerging quickly with M&A and alliances.
The market will concentrate more on Tier 1 & 2. The rest of CROs need to seek M&A and/or alliances with others, to move up in this market.
Increasing global studies and preferred relationships between pharma and CRO will be the key for CRO to survive.
2. Clinical Trial Trend
3. CRO Market
4. Industry Association
5. CRO Players
- Tier 1 CRO Players
- Tier 2 CRO Players
6. Emerging CRO Players
7. “The rest of Global CRO group”
8. Outsourcing Trend in Pharma
9. Future Prospect